Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | TSHR | P16473 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223716 | 0.84 | KMT2A (0.69) | KMT2ATSHRKDM4EALDH1A1GAA | |
| SCHEMBL29575490 | 0.84 | GAA (0.97) | KMT2ATSHRKDM4EALDH1A1GAA | |
| SCHEMBL26100269 | 0.83 | KMT2A (0.67) | KMT2ATSHRALDH1A1MEN1MAPT | |
| SCHEMBL7252459 | 0.83 | KMT2A (0.67) | KMT2ATSHRALDH1A1HPGDMEN1 | |
| SCHEMBL18711913 | 0.82 | KMT2A (0.66) | KMT2ATSHRKDM4EALDH1A1GAA | |
| Ammonia Solution, Strong SCHEMBL26132989 | 0.82 | KMT2A (0.66) | KMT2ATSHRALDH1A1MEN1MAPT | |
| SCHEMBL7252394 | 0.81 | KMT2A (0.64) | KMT2ATSHRALDH1A1HPGDMEN1 | |
| SCHEMBL7661191 | 0.80 | RAB9A (0.72) | KMT2ATSHRKDM4EALDH1A1GAA | |
| SCHEMBL29951820 | 0.80 | TSHR (0.67) | KMT2ATSHRKDM4EALDH1A1GAA | |
| SCHEMBL1001171 | 0.80 | RAB9A (0.72) | KMT2ATSHRKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | VALO HEALTH, INC. (US) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | KMT2A 888/4885TSHR 3065/4885KDM4E 2054/4885 |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | NAMPT, NAPRT, NNMT | KMT2A 888/4885TSHR 3065/4885KDM4E 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.